Neil E Fleshner
Overview
Explore the profile of Neil E Fleshner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
268
Citations
5100
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernardino R, van der Kwast T, Fleshner N
Eur Urol
. 2025 Jan;
PMID: 39890554
The detection of intraductal carcinoma and cribriform pattern in prostate cancer biopsies and imaging remains challenging, affecting risk stratification and treatment. Further research is essential.
2.
Hansen A, Probst S, Beauregard J, Viglianti B, Michalski J, Tagawa S, et al.
Front Oncol
. 2025 Jan;
14():1483953.
PMID: 39839782
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase...
3.
Dong L, Lajkosz K, Sanchez-Salas R, Kuk C, Xu W, Tiwari R, et al.
J Natl Compr Canc Netw
. 2024 Nov;
22(10).
PMID: 39546889
Background: Historically, Asia had a lower prostate cancer (PCa) incidence and mortality compared with Western countries, but the gap is narrowing. Paradoxically, Asians have been reported to present with more...
4.
Villegas E, Lajkosz K, Din S, Kuk C, Chan A, Kwong J, et al.
J Urol
. 2024 Oct;
213(3):295-303.
PMID: 39470318
Purpose: Patients with Ta low-grade (LG) nonmuscle-invasive bladder cancer (NMIBC) rarely develop metastases or die of it. Long-term data are scant and length of follow-up poorly defined. Materials And Methods:...
5.
Bernardino R, Yin L, Lajkosz K, Cockburn J, Wettstein M, Sayyid R, et al.
Prostate Cancer Prostatic Dis
. 2024 Oct;
28(1):187-192.
PMID: 39433886
Background: Intraductal carcinoma (IDC) and cribriform pattern (Crib) of prostate cancer are increasingly recognized as independent prognosticators of poor outcome, both in prostate biopsies and radical prostatectomy (RP) specimens. Objective:...
6.
7.
Bernardino R, Lajkosz K, Yin L, Sayyid R, Wettstein M, Randhawa H, et al.
J Nucl Med
. 2024 Sep;
65(11):1731-1739.
PMID: 39327019
In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to...
8.
Sayyid R, Bernardino R, Chavarriaga J, Kumar R, Randhawa H, Wettstein M, et al.
World J Urol
. 2024 Jul;
42(1):418.
PMID: 39023778
Purpose: To compare disease-free survival (DFS), overall survival (OS), and adverse events (AEs) among muscle-invasive urothelial carcinoma (MIUC) patients receiving adjuvant immune checkpoint inhibitors (ICIs) versus placebo/observation following radical surgery....
9.
Hof J, Vermeulen S, van der Heijden A, Verhaegh G, Dyrskjot L, Catto J, et al.
Bladder Cancer
. 2024 Jul;
9(1):59-71.
PMID: 38994482
Background: Various germline genetic variants are associated with the prognosis of non-muscle invasive bladder cancer (NMIBC). Germline variants in genes frequently somatically mutated in bladder cancer have not been studied...
10.
Sayyid R, Bernardino R, Chavarriaga J, Gleave A, Kumar R, Fleshner N
Transl Androl Urol
. 2024 Jun;
13(5):884-888.
PMID: 38855585
No abstract available.